Calliditas Archives -

Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA

FDA sets September review date for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/

Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN),

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

https://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/

Swedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next

Calliditas plans to file rare kidney disease drug Nefecon after phase 3 success

https://pharmaphorum.com/news/calliditas-plans-to-file-rare-disease-drug-nefecon-after-phase-3-success/

Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease

Calliditas hits $90m jackpot as biotech IPO craze continues

https://pharmaphorum.com/news/calliditas-hits-90m-jackpot-as-biotech-ipo-craze-continues/

European regulators have granted a fast path to market for Calliditas Therapeutics’ potential rare kidney disease drug, Nefecon,

European regulators grant fast path to market for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/european-grant-fast-path-to-market-for-calliditas-rare-kidney-disease-drug/

The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease,

FDA agrees to downsized trial for Calliditas’ rare disease drug

https://pharmaphorum.com/news/fda-agrees-to-downsized-trial-for-calliditas-rare-disease-drug/

Calliditas